Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: Dual roles in antiapoptosis and cell repair

Archives of Surgery

Volumn 141, Issue 11, 2006, Pages 1077-1084

  Ho, David W ^a   Zhen, Fan Yang ^a   Chi, Keung Lau ^a   Ka, Ho Tam ^a   To, Jensen Y ^a   Poon, Ronnie T ^a   Sheung, Tat Fan ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CARDIOTROPHIN 1; CYCLIN D1; GALACTOSAMINE; GLYCOPROTEIN GP 130; HEAT SHOCK PROTEIN 90;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD CLOTTING TIME; BODY WEIGHT; CELL CULTURE; CELL LEVEL; CELL PROLIFERATION; CELL REGENERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; LIVER CELL; LIVER FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; SURVIVAL RATE;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GALACTOSIDASES; HEPATOCYTES; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; MALE; RATS; SURVIVAL RATE;

EID: 33751241137     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.11.1077     Document Type: Article

References (28)

1. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis. 1996;16:343-348.
2. O'Grady JG. Acute liver failure. In: O'Grady JG, Lake JR, Howdle PD, eds. Comprehensive Clinical Hepatology. London, England: Mosby-Yearbook Inc; 2000: 30.1-30.20.
3. Stockmann HB, Hiemstra CA, Marquet RL, IJzermans JN. Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg. 2000;231:460-470.
4. Ho DW, Fan ST, To J, et al. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut. 2002;50:869-876.
5. van de Kerkhove MP, Hoekstra R, Chamuleau RA, van Gulik TM. Clinical application of bioartificial liver support systems. Ann Surg. 2004;240:216-230.
6. Jin H, Yang R, Keller GA, et al. In vivo effects of cardiotrophin-1. Cytokine. 1996;8:920-926.
7. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway: divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem. 1997;272:5783-5791.
8. Freed DH, Cunnington RH, Dangerfield AL, Sutton JS, Dixon IM. Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc Res. 2005;65:782-792.
9. Liao Z, Brar BK, Cai Q, et al. Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion. Cardiovasc Res. 2002;53:902-910.
10. Toh R, Kawashima S, Kawai M, et al. Transplantation of cardiotrophin-1-expressing myoblasts to the left ventricular wall alleviates the transition from compensatory hypertrophy to congestive heart failure in Dahl salt-sensitive hypertensive rats. J Am Coll Cardiol. 2004;43:2337-2347.
11. Nomura N, Asano M, Saito T, et al. Cardiotrophin-1 is a prophylactic against the development of chronic hypoxic pulmonary hypertension in rats. Ann Thorac Surg. 2003;76:237-243.
12. Lesbordes JC, Cifuentes-Diaz C, Miroglio A, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2003;12:1233-1239.
13. Bustos M, Beraza N, Lasarte JJ, et al. Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology. 2003;125:192-201.
14. Beraza N, Marques JM, Martinez-Anso E, Iniguez M, Prieto J, Bustos M. Interplay among cardiotrophin-1, prostaglandins, and vascular endothelial growth factor in rat liver regeneration. Hepatology. 2005;41:460-469.
15. Dell RB, Holleran S, Ramakrishnan R. Sample size determination. ILAR J. 2002;43:207-213.
16. Yu CC, Woods AL, Levison DA. The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J. 1992;24:121-131.
17. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem. 1999;274:23013-23019.
18. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997;276:60-66.
19. Campbell JS, Prichard L, Schaper F, et al. Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest. 2001;107:1285-1292.
20. Toth G, Yang H, Anguelov RA, Vettraino J, Wang Y, Acsadi G. Gene transfer of glial cell-derived neurotrophic factor and cardiotrophin-1 protects PC12 cells from injury: involvement of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase pathways. J Neurosci Res. 2002;69:622-632.
21. κB. J Biol Chem. 2001;276:37621-37629.
22. Rind HB, von Bartheld CS. Target-derived cardiotrophin-1 and insulin-like growth factor-I promote neurite growth and survival of developing oculomotor neurons. Mol Cell Neurosci. 2002;19:58-71.
23. Yang ZF, Ho DW, Lam CT, et al. Identification of brain-derived neurotrophic factor (BDNF) as a novel functional protein in hepatocellular carcinoma. Cancer Res. 2005;65:219-225.
24. Yang ZF, Poon RT, Luo Y, et al. Upregulation of vascular endothelial growth factor (VEGF) in small-for-size liver grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol. 2004;173:2507-2515.
25. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100:13791-13796.
26. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation. 2002;106:1442-1446.
27. Tsuruda T, Jougasaki M, Boerrigter G, et al. Cardiotrophin-1 stimulation of cardiac fibroblast growth: roles for glycoprotein 130/leukemia inhibitory factor receptor and the endothelin type A receptor. Circ Res. 2002;90:128-134.
28. Sen S, Ratnaraj N, Davies NA, et al. Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS). Epilepsia. 2003;44:265-267.